p53 is an important factor for the radiosensitization effect of 2-deoxy-D-glucose

International Journal of Oncology

Volumn 35, Issue 3, 2009, Pages 609-615

  Sinthupibulyakit, Chompunoot ^a,d   Grimes, Kristopher R ^a   Domann, Frederick E ^c   Xu, Yong ^a   Fang, Fang ^b   Ittarat, Wanida ^d   St Clair, Daret K ^a   St Clair, William ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d MAHIDOL UNIVERSITY   (Thailand)

Author keywords

2 deoxy D glucose; Clonogenic survival; Lung cancer; p53; Radiation

Indexed keywords

DEOXYGLUCOSE; PROTEIN P53; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; FEMALE; GLYCOLYSIS; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; TUMOR REGRESSION;

ANIMALS; ANTIMETABOLITES; BLOTTING, WESTERN; CELL LINE, TUMOR; DEOXYGLUCOSE; FEMALE; GLYCOLYSIS; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; RADIATION TOLERANCE; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70349153884     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000372     Document Type: Article

References (41)

1. Pisani P, Parkin DM, Bray F and Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83: 18-29, 1999.
2. Cancer Facts & Figures 2008. American Cancer Society, 2008.
3. Travis WD, Lubin J, Ries L and Devesa S: United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer 77: 2464-2470, 1996.
4. Spira A and Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med 350: 379-392, 2004.
5. Younes M, Brown RW, Stephenson M, Gondo M and Cagle PT: Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 80: 1046-1051, 1997.
6. Warburg O: On the origin of cancer cells. Science 123: 309-314, 1956.
7. Weber G: Enzymology of cancer cells (second of two parts). N Engl J Med 296: 541-551, 1977.
8. Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A and Saavedra E: Energy metabolism in tumor cells. FEBS J 274: 1393-1418, 2007.
9. Kroemer G and Pouyssegur J: Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13: 472-482, 2008.
10. Cuezva JM, Chen G, Alonso AM, et al: The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis. Carcinogenesis 25: 1157-1163, 2004.
11. Lopez-Rios F, Sanchez-Arago M, Garcia-Garcia E, et al: Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res 67: 9013-9017, 2007.
12. Zhang XD, Deslandes E, Villedieu M, et al: Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro. Anticancer Res 26: 3561-3566, 2006.
13. Aft RL, Zhang FW and Gius D: Evaluation of 2-deoxy-Dglucose as a chemotherapeutic agent: mechanism of cell death. Br J Cancer 87: 805-812, 2002.
14. Jain VK, Kalia VK, Gopinath PM, Naqvi S and Kucheria K: Optimization of cancer therapy: Part III - effects of combining 2-deoxy-D-glucose treatment with gamma-irradiation on normal mice. Indian J Exp Biol 17: 1320-1325, 1979.
15. Kalia VK, Jain VK and Otto FJ: Optimization of cancer therapy: Part IV - effects of 2-deoxy-D-glucose on radiation induced chromosomal damage in PHA-stimulated peripheral human leukocytes. Indian J Exp Biol 20: 884-888, 1982.
16. Singh SP, Singh S and Jain V: Effects of 5-bromo-2-deoxyuridine and 2-deoxy-D-glucose on radiation-induced micronuclei in mouse bone marrow. Int J Radiat Biol 58: 791-797, 1990.
17. Swamy RK, Manickam J, Adhikari JS and Dwarakanath BS: Glycolytic inhibitor, 2-deoxy-D-glucose, does not enhance radiation-induced apoptosis in mouse thymocytes and splenocytes in vitro. Indian J Exp Biol 43: 686-692, 2005.
18. Liu H, Hu YP, Savaraj N, Priebe W and Lampidis TJ: Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry 40: 5542-5547, 2001.
19. Liu H, Savaraj N, Priebe W and Lampidis TJ: Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Biochem Pharmacol 64: 1745-1751, 2002.
20. Maher JC, Krishan A and Lampidis TJ: Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol 53: 116-122, 2004.
21. Nelson CA, Wang JQ, Leav I and Crane PD: The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxyglucose retention in murine tumor models. Nucl Med Biol 23: 533-541, 1996.
22. Heminger K, Jain V, Kadakia M, Dwarakanath B and Berberich SJ: Altered gene expression induced by ionizing radiation and glycolytic inhibitor 2-deoxy-glucose in a human glioma cell line: implications for radio sensitization. Cancer Biol Ther 5: 815-823, 2006.
23. 2+ and reactive oxygen intermediates as messengers. FEBS Lett 392: 129-136, 1996.
24. Lin X, Zhang F, Bradbury CM, et al: 2-Deoxy-D-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. Cancer Res 63: 3413-3417, 2003.
25. Coleman MC, Asbury CR, Daniels D, et al: 2-deoxy-D-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer. Free Radic Biol Med 44: 322-331, 2008.
26. Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ and Spitz DR: 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res 67: 3364-3370, 2007.
27. Maschek G, Savaraj N, Priebe W, et al: 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 64: 31-34, 2004.
28. Dwarkanath BS, Zolzer F, Chandana S, et al: Heterogeneity in 2-deoxy-D-glucose-induced modifications in energetics and radiation responses of human tumor cell lines. Int J Radiat Oncol Biol Phys 50: 1051-1061, 2001.
29. Jha B and Pohlit W: Reversibility of inhibition of DNA double strand break repair by 2-deoxy-D-glucose in Ehrlich ascites tumour cells. Int J Radiat Biol 63: 459-467, 1993.
30. Mohanti BK, Rath GK, Anantha N, et al: Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys 35: 103-111, 1996.
31. Bensaad K and Vousden KH: p53: new roles in metabolism. Trends Cell Biol 17: 286-291, 2007.
32. Jones RG, Plas DR, Kubek S, et al: AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18: 283-293, 2005.
33. Matoba S, Kang JG, Patino WD, et al: p53 regulates mitochondrial respiration. Science 312: 1650-1653, 2006.
34. Kondoh H, Lleonart ME, Gil J, et al: Glycolytic enzymes can modulate cellular life span. Cancer Res 65: 177-185, 2005.
35. Bensaad K, Tsuruta A, Selak MA, et al: TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126: 107-120, 2006.
36. Ahmad IM, Abdalla MY, Aykin-Burns N, et al: 2-Deoxyglucose combined with wild-type p53 overexpression enhances cytotoxicity in human prostate cancer cells via oxidative stress. Free Radic Biol Med 44: 826-834, 2008.
37. Kawauchi K, Araki K, Tobiume K and Tanaka N: p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol 10: 611-618, 2008.
38. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE and Chumakov PM: The antioxidant function of the p53 tumor suppressor. Nat Med 11: 1306-1313, 2005.
39. Vousden KH and Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol 8: 275-283, 2007.
40. Simons AL, Fath MA, Mattson DM, et al: Enhanced response of human head and neck cancer xenograft tumors to cisplatin combined with 2-deoxy-D-glucose correlates with increased 18F-FDG uptake as determined by PET imaging. Int J Radiat Oncol Biol Phys 69: 1222-1230, 2007.
41. Brambilla C, Fievet F, Jeanmart M, et al: Early detection of lung cancer: role of biomarkers. Eur Respir J (Suppl) 39: S36-S44, 2003.